Clinical Research Papers:
Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors
Metrics: PDF 1304 views | HTML 1905 views | ?
Xiaoliang Zhao1,*, Xiaohua Wen2,*, Wei Wei1, Yulong Chen1, Jianquan Zhu1 and Changli Wang1
1 Department of Lung Cancer Tianjin Medical University Cancer Institute and Hospital, Tianjin Lung Cancer Center, Tianjin Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer Tianjin, Tianjin, P.R. China
2 Tianjin University of Traditional Chinese Medicine, Tianjin, P.R. China
* Xiaoliang Zhao and Xiaohua Wen contributed equally to this work
Changli Wang, email:
Keywords: metastatic lung tumor, surgical treatment, prognostic factor
Received: December 09, 2016 Accepted: January 17, 2017 Published: January 26, 2017
The clinical characteristics of metastatic lung tumors are not well understood. To explore the surgical indications, surgical modes, and factors that influence postoperative outcomes, we analyzed clinical data from 42 patients with metastatic lung tumors who received surgical treatment at Tianjin Medical University Cancer Institute and Hospital between January 2000 and January 2014. Gender, age, nature of resections, surgical mode, smoking index, disease-free intervals (DFIs), number of metastatic lesions, and lymph node metastases were analyzed. Patients were followed for 6 to 98 months. We found that surgical treatment is feasible for resectable metastatic lung tumors, though postoperative radiochemotherapy had no significant effect on postoperative survival rates among patients with metastatic lung tumors. No patients died perioperatively. The 1-year, 3-year, and 5-year survival rates after surgical resection of metastatic lung tumors were 88.1%, 45.7%, and 34.6%, respectively. Univariate analysis indicated that DFIs and lymph node metastasis correlated with patient prognoses, while multivariate analysis indicated these two variables were independent prognostic factors. Thus surgical treatment may be indicated, depending on patients’ specific condition, to lengthen DFIs in patients with metastatic lung tumors with or without evident lymph node metastasis.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.